Modern Diagnostic & Research Centre Limited is a healthcare diagnostics service provider offering pathology and radiology testing services. The company earns revenue by providing diagnostic tests to individual patients, hospitals, healthcare providers, and corporate clients. Its services are used for disease diagnosis, prevention, monitoring, and clinical decision-making through advanced imaging and laboratory testing facilities across India.

The Company is led by Promoter, i.e., MR. DEVENDRA SINGH YADAV, MRS. DEEPALI YADAV, MRS ASHA YADAV AND MR. JITENDRA SINGH

The Revenues from operations for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 2,267.23 Lakh, ₹ 7,880.46 Lakh, â‚¹ 6,867.21 Lakh, and ₹ 5,660.53 Lakh, The EBITDA for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 586.19 Lakh, ₹ 1,796.25 Lakh, ₹ 1,105.18 Lakh, and ₹ -98.77 Lakh, The Profit after Tax for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 299.82 Lakh, ₹ 896.81 Lakh, â‚¹ 579.48 Lakh, and ₹ -573.20 Lakh, respectively. This indicates a steady growth in financial performance.

 The Company Key Performance Indicates the pre-issue EPS of   â‚¹ 8.15 and post-issue EPS of ₹ 5.94 for FY25. The pre-issue P/E ratio is 11.04x,while the post-issue P/E ratio is 15.15x against the Industry P/E ratio is 72.36x The company's ROE for FY25 is 55.21% and RoNW is 12.39% The  Annualised EPS is ₹ -8.68x and P/E is 43.27%x.  These metrics suggest that the IPO is Fully priced. 


The Grey Market Premium (GMP) of Modern Diagnostic & Research Centre showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Modern Diagnostic & Research Centre Limited IPO for Listing gain or Long Term Purposes.